Biosimilars

Debbie Stern of Rxperts highlights the various "unknowns" surrounding the potential cost savings of biosimilar products, such as interchangeability and the possible need for additional clinical trials.

The Biotechnology Industry Organization (BIO) and Oregon Bioscience Association (Oregon Bio) commend Oregon Governor John Kitzhaber for signing legislation designed to address the regulatory issues related to the interchangeability of biological medicines.

Illinois is now the 13th state to avoid enacting legislation that would slow patient access to biosimilars, which are new, affordable versions of costly brand biologic medicines that treat cancer, immune disorders and other complex diseases.

A bill passed by the Florida legislature would allow pharmacists to substitute biosimilars for brand-named biologics provided that a number of criteria are met.

A bill passed by the Florida legislature would allow pharmacists to substitute biosimilars for brand-name biologics provided that a number of criteria are met.

The Generic Pharmaceutical Association suggests that a eport on the global biosimilar market demonstrates the need for action to make biosimilar versions of biologic medicines available.

US manufacturers prepare for expanding biosimilar market opportunities as this exciting landscape takes shape. The production of biosimilars poses challenges as pharma looks to curb health care spending.

The industry is watching how biosimilars will affect the market and the challenges that lie ahead.

The global market for biosimilars is predicted to grow to $3.7 billion by 2015, according to a recent report by Grant Thornton. Will proposed legislation regarding the interchangeability of biosimilars thwart United States innovation and leave us far behind our European counterparts?

March 2013 Meetings

The generic marketplace remains dynamic and complicated, as patent expirations,interest in biosimilars, and international competition spur major changes.

To get perspective on the ACA ruling's impact on specialty pharmacy, Specialty Pharmacy Times interviewed D'vorah Graeser, PhD, about the Biologics Price Competition and Innovation Act (BPCIA).

Employers are concerned with worker health behaviors and want to control spending on expensive specialty medications, according to a new survey released by Express Scripts.

Pharmacists should be knowledgeable about the different approaches used to modify biopharmaceuticals and how they affect stability, dosing, safety, and efficacy.

Payer response to new entrants to the multiple sclerosis (MS) market is mixed as some believe that there remain meaningful, major unmet needs in the MS category, according to The Zitter Group's Spring 2011 Managed Care Biologics and Injectables Index.